Intervention

Olmesartan medoxomil

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 19 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials19

Recruiting0

Common conditions18

Lead sponsors shown10

Clinical trials

19 shown

Fimasartan Achieving SBP Target (FAST) StudyNCT02495324 · 2015-06-01

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential HypertensionNCT02407210 · 2015-01-01

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mgNCT01611077 · 2012-01-01

Telmisartan, Amlodipine and Flow Mediated DilationNCT01180205 · 2010-08-01

Angiotensin II Blockade and Inflammation in ObesityNCT01684748 · 2009-02-01

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With HypertensionNCT00649389 · 2008-05-01

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With HydrochlorothiazideNCT00796159 · 2007-07-01

Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled HypertensionNCT00523744 · 2007-07-01

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With HypertensionNCT00412932 · 2006-12-01

Olmesartan Pediatric Pharmacokinetic (PK) StudyNCT00151814 · 2005-09-01

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel BlockerNCT00185120 · 2005-09-01

OlmeSartan and Calcium Antagonists Randomized (OSCAR) StudyNCT00134160 · 2005-08-01

Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe HypertensionNCT00185133 · 2005-05-01

Olmesartan Medoxomil in Diabetes MellitusNCT00185159 · 2004-10-01

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With HypertensionNCT00185068 · 2004-03-01

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to InsulinNCT00185094 · 2004-02-01

Olmesartan Medoxomil in Hypertension and Renal ImpairmentNCT00151827 · 2003-08-01

Olmesartan Medoxomil and Diabetic NephropathyNCT00362960 · 2003-05-01

Olmesartan Medoxomil in AtherosclerosisNCT00185185 · 2001-11-01

Common conditions

Hypertension13 Essential Hypertension3 Atherosclerotic Cardiovascular Disease1 Cardiovascular Disease1 Cardiovascular Diseases1 Diabetes Mellitus, Type 21 Diabetic Nephropathy1 Essential,Hypertension1 Insulin Resistance1 Kidney Disease1 Metabolic Syndrome1 Obese1 Overweight1 Prehypertension1 Proteinuria1 Renal Disease1 Renal Impairment1 Type 2 Diabetes Mellitus1

Leading sponsors

Daiichi Sankyo 7 Sankyo Pharma Gmbh 4 Boryung Pharmaceutical Co., Ltd 1 Institut für Pharmakologie und Präventive Medizin 1 Jiangsu HengRui Medicine Co., Ltd. 1 Johannes Gutenberg University Mainz 1 Novartis 1 OSCAR Study 1 Pfizer 1 Virginia Polytechnic Institute and State University 1

Trial status mix

COMPLETED17

UNKNOWN2

Phase mix

PHASE49

PHASE38

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.